Cargando…

Gadolinium Neutron Capture Therapy (GdNCT) Agents from Molecular to Nano: Current Status and Perspectives

[Image: see text] (157)Gd (natural abundance = 15.7%) has the highest thermal neutron capture cross section (σ) of 254,000 barns (1 barn = 10(–28) m(2)) among stable (nonradioactive) isotopes in the periodic table. Another stable isotope, (155)Gd (natural abundance = 14.8%), also has a high σ value...

Descripción completa

Detalles Bibliográficos
Autores principales: Ho, Son Long, Yue, Huan, Tegafaw, Tirusew, Ahmad, Mohammad Yaseen, Liu, Shuwen, Nam, Sung-Wook, Chang, Yongmin, Lee, Gang Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793081/
https://www.ncbi.nlm.nih.gov/pubmed/35097254
http://dx.doi.org/10.1021/acsomega.1c06603
_version_ 1784640518989283328
author Ho, Son Long
Yue, Huan
Tegafaw, Tirusew
Ahmad, Mohammad Yaseen
Liu, Shuwen
Nam, Sung-Wook
Chang, Yongmin
Lee, Gang Ho
author_facet Ho, Son Long
Yue, Huan
Tegafaw, Tirusew
Ahmad, Mohammad Yaseen
Liu, Shuwen
Nam, Sung-Wook
Chang, Yongmin
Lee, Gang Ho
author_sort Ho, Son Long
collection PubMed
description [Image: see text] (157)Gd (natural abundance = 15.7%) has the highest thermal neutron capture cross section (σ) of 254,000 barns (1 barn = 10(–28) m(2)) among stable (nonradioactive) isotopes in the periodic table. Another stable isotope, (155)Gd (natural abundance = 14.8%), also has a high σ value of 60,700 barns. These σ values are higher than that of (10)B (3840 barns, natural abundance = 19.9%), which is currently used as a neutron-absorbing isotope for boron neutron capture therapy agents. Energetic particles such as electrons and γ-rays emitted from Gd-isotopes after neutron beam absorption kill cancer cells by damaging DNAs inside cancer-cell nuclei without damaging normal cells if Gd-chemicals are positioned in cancer cells. To date, various Gd-chemicals such as commercial Gd-chelates used as magnetic resonance imaging contrast agents, modified Gd-chelates, nanocomposites containing Gd-chelates, fullerenes containing Gd, and solid-state Gd-nanoparticles have been investigated as gadolinium neutron capture therapy (GdNCT) agents. All GdNCT agents had exhibited cancer-cell killing effects, and the degree of the effects depended on the GdNCT agents used. This confirms that GdNCT is a promising cancer therapeutic technique. However, the commercial Gd-chelates were observed to be inadequate in clinical use because of their low accumulation in cancer cells due to their extracellular and noncancer targeting properties and rapid excretion. The other GdNCT agents exhibited higher accumulation in cancer cells, compared to Gd-chelates; consequently, they demonstrated higher cancer-cell killing effects. However, they still displayed limitations such as poor specificity to cancer cells. Therefore, continuous efforts should be made to synthesize GdNCT agents suitable in clinical applications. Herein, the principle of GdNCT, current status of GdNCT agents, and general design strategy for GdNCT agents in clinical use are discussed and reviewed.
format Online
Article
Text
id pubmed-8793081
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-87930812022-01-28 Gadolinium Neutron Capture Therapy (GdNCT) Agents from Molecular to Nano: Current Status and Perspectives Ho, Son Long Yue, Huan Tegafaw, Tirusew Ahmad, Mohammad Yaseen Liu, Shuwen Nam, Sung-Wook Chang, Yongmin Lee, Gang Ho ACS Omega [Image: see text] (157)Gd (natural abundance = 15.7%) has the highest thermal neutron capture cross section (σ) of 254,000 barns (1 barn = 10(–28) m(2)) among stable (nonradioactive) isotopes in the periodic table. Another stable isotope, (155)Gd (natural abundance = 14.8%), also has a high σ value of 60,700 barns. These σ values are higher than that of (10)B (3840 barns, natural abundance = 19.9%), which is currently used as a neutron-absorbing isotope for boron neutron capture therapy agents. Energetic particles such as electrons and γ-rays emitted from Gd-isotopes after neutron beam absorption kill cancer cells by damaging DNAs inside cancer-cell nuclei without damaging normal cells if Gd-chemicals are positioned in cancer cells. To date, various Gd-chemicals such as commercial Gd-chelates used as magnetic resonance imaging contrast agents, modified Gd-chelates, nanocomposites containing Gd-chelates, fullerenes containing Gd, and solid-state Gd-nanoparticles have been investigated as gadolinium neutron capture therapy (GdNCT) agents. All GdNCT agents had exhibited cancer-cell killing effects, and the degree of the effects depended on the GdNCT agents used. This confirms that GdNCT is a promising cancer therapeutic technique. However, the commercial Gd-chelates were observed to be inadequate in clinical use because of their low accumulation in cancer cells due to their extracellular and noncancer targeting properties and rapid excretion. The other GdNCT agents exhibited higher accumulation in cancer cells, compared to Gd-chelates; consequently, they demonstrated higher cancer-cell killing effects. However, they still displayed limitations such as poor specificity to cancer cells. Therefore, continuous efforts should be made to synthesize GdNCT agents suitable in clinical applications. Herein, the principle of GdNCT, current status of GdNCT agents, and general design strategy for GdNCT agents in clinical use are discussed and reviewed. American Chemical Society 2022-01-12 /pmc/articles/PMC8793081/ /pubmed/35097254 http://dx.doi.org/10.1021/acsomega.1c06603 Text en © 2022 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by-nc-nd/4.0/Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Ho, Son Long
Yue, Huan
Tegafaw, Tirusew
Ahmad, Mohammad Yaseen
Liu, Shuwen
Nam, Sung-Wook
Chang, Yongmin
Lee, Gang Ho
Gadolinium Neutron Capture Therapy (GdNCT) Agents from Molecular to Nano: Current Status and Perspectives
title Gadolinium Neutron Capture Therapy (GdNCT) Agents from Molecular to Nano: Current Status and Perspectives
title_full Gadolinium Neutron Capture Therapy (GdNCT) Agents from Molecular to Nano: Current Status and Perspectives
title_fullStr Gadolinium Neutron Capture Therapy (GdNCT) Agents from Molecular to Nano: Current Status and Perspectives
title_full_unstemmed Gadolinium Neutron Capture Therapy (GdNCT) Agents from Molecular to Nano: Current Status and Perspectives
title_short Gadolinium Neutron Capture Therapy (GdNCT) Agents from Molecular to Nano: Current Status and Perspectives
title_sort gadolinium neutron capture therapy (gdnct) agents from molecular to nano: current status and perspectives
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793081/
https://www.ncbi.nlm.nih.gov/pubmed/35097254
http://dx.doi.org/10.1021/acsomega.1c06603
work_keys_str_mv AT hosonlong gadoliniumneutroncapturetherapygdnctagentsfrommoleculartonanocurrentstatusandperspectives
AT yuehuan gadoliniumneutroncapturetherapygdnctagentsfrommoleculartonanocurrentstatusandperspectives
AT tegafawtirusew gadoliniumneutroncapturetherapygdnctagentsfrommoleculartonanocurrentstatusandperspectives
AT ahmadmohammadyaseen gadoliniumneutroncapturetherapygdnctagentsfrommoleculartonanocurrentstatusandperspectives
AT liushuwen gadoliniumneutroncapturetherapygdnctagentsfrommoleculartonanocurrentstatusandperspectives
AT namsungwook gadoliniumneutroncapturetherapygdnctagentsfrommoleculartonanocurrentstatusandperspectives
AT changyongmin gadoliniumneutroncapturetherapygdnctagentsfrommoleculartonanocurrentstatusandperspectives
AT leegangho gadoliniumneutroncapturetherapygdnctagentsfrommoleculartonanocurrentstatusandperspectives